Inventor · disambiguated record
Katrina Lee Jackson
Also filed as: JACKSON KATRINA L · JACKSON KATRINA LEE
25 granted patents·10 pending applications·207 citations·filing 2013–2024
96Inventor score
Top patents by PatentIndex Score
35 records- 0198US9376448B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2013·Granted Jun 28, 2016·46 cites·10 claims
- 0297US9925188B2DNA-PK inhibitors and uses thereofVERTEX PHARMA·Filed 2016·Granted Mar 27, 2018·24 cites·18 claims
- 0396US9592232B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2014·Granted Mar 14, 2017·24 cites·13 claims
- 0495US9359380B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2014·Granted Jun 7, 2016·19 cites·25 claims
- 0595US9340557B2Substituted quinoxaline DNA-PK inhibitorsVERTEX PHARMA·Filed 2014·Granted May 17, 2016·19 cites·26 claims
- 0695US9296701B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2013·Granted Mar 29, 2016·21 cites·17 claims
- 0794US9878993B2DNA-PK inhibitors for treatment of cancerVERTEX PHARMA·Filed 2016·Granted Jan 30, 2018·10 cites·7 claims
- 0893US11691972B2Compounds for targeted degradation of BRD9C4 THERAPEUTICS INC·Filed 2021·Granted Jul 4, 2023·5 cites·10 claims
- 0993US10786512B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2019·Granted Sep 29, 2020·3 cites·8 claims
- 1092US10973830B2Substituted quinoxaline DNA-PK inhibitorsVERTEX PHARMA·Filed 2019·Granted Apr 13, 2021·3 cites·23 claims
- 1192US10076521B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2017·Granted Sep 18, 2018·7 cites·21 claims
- 1291US10501439B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2018·Granted Dec 10, 2019·5 cites·18 claims
- 1391US10442791B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2018·Granted Oct 15, 2019·5 cites·13 claims
- 1491US10391095B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2018·Granted Aug 27, 2019·5 cites·9 claims
- 1590US9987284B2Substituted benzooxadiazole DNA-PK inhibitorsVERTEX PHARMA·Filed 2016·Granted Jun 5, 2018·5 cites·23 claims
- 1689US12157735B2Compounds for targeted degradation of BRD9C4 THERAPEUTICS INC·Filed 2022·Granted Dec 3, 2024·1 cites·23 claims
- 1789US10258627B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2017·Granted Apr 16, 2019·4 cites·19 claims
- 1888US12049464B2Compounds for targeted degradation of BRD9C4 THERAPEUTICS INC·Filed 2022·Granted Jul 30, 2024·1 cites·11 claims
- 1986US12251387B2Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitorsVERTEX PHARMA·Filed 2023·Granted Mar 18, 2025·0 cites·20 claims
- 2081US12486253B2Therapeutics for the degradation of mutant BRAFC4 THERAPEUTICS INC·Filed 2024·Granted Dec 2, 2025·0 cites·4 claims
- 2181US2025084081A1Compounds for targeted degradation of brd9C4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2277US2021236505A1Substituted quinoxaline dna-pk inhibitorsVERTEX PHARMA·Filed 2021·Application pending·0 cites
- 2376US11813267B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2020·Granted Nov 14, 2023·0 cites·19 claims
- 2476US11021465B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2019·Granted Jun 1, 2021·0 cites·22 claims
- 2575US11008305B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2019·Granted May 18, 2021·0 cites·20 claims
- 2670US2024199581A1Therapeutics for the degradation of mutant brafC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2769US2018311254A1Dna-pk inhibitorsVERTEX PHARMA·Filed 2018·Application pending·0 cites
- 2864US2016354381A1Dna-pk inhibitorsObligated Assignee·Filed 2016·Application pending·0 cites
- 2963US2025121070A1Compounds for the targeted degradation of smarca2C4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3061US12454521B2Targeted protein degradationC4 THERAPEUTICS INC·Filed 2021·Granted Oct 28, 2025·0 cites·25 claims
- 3160US2023372496A1Tricyclic heterobifunctional compounds for degradation of targeted proteinsC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3259US2024245677A1Selected compounds for targeted degradation of brd9C4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3350US2021198256A1Compounds for the degradation of brd9 or mth1C4 THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3446US12005127B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2019·Granted Jun 11, 2024·0 cites·48 claims
- 3539US2018251431A11,3-substituted pyrazole compounds useful for reduction of very long chain fatty acid levelsVERTEX PHARMA·Filed 2017·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →